Related Experiment Video

Updated: Aug 15, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Novel agents for the treatment of advanced kidney cancer

Matthew M Cooney1, Scot C Remick, Nicholas J Vogelzang

  • 1Case Comprehensive Cancer Center, Cleveland, OH 44106, USA.

Clinical Advances in Hematology & Oncology : H&O
|September 16, 2005
PubMed

Insights

Advanced kidney cancer causes over 12,000 deaths annually. Current immunotherapies have low response rates, but novel agents in clinical trials show promise for treating this refractory disease.

Area of Science:

  • Oncology
  • Nephrology
  • Immunology

Background:

  • Advanced kidney cancer leads to significant mortality in the US.
  • Current standard treatments like interleukin-2 and interferon-alpha offer limited efficacy.
  • Refractory advanced kidney cancer necessitates exploration of novel therapeutic strategies.

Purpose of the Study:

  • To review emerging therapeutic agents for advanced kidney cancer.
  • To highlight promising novel treatments currently in clinical trials.
  • To discuss the potential of new compounds in a refractory disease setting.

Main Methods:

  • Literature review of clinical trials and research on advanced kidney cancer treatments.
  • Analysis of novel therapeutic agents including antiangiogenic compounds, kinase inhibitors, and antimicrotubule agents.
  • Synthesis of current research findings on promising treatments for refractory kidney cancer.

Main Results:

  • Several novel agents demonstrate potential in clinical trials for advanced kidney cancer.
  • Antiangiogenic agents, raf kinase pathway inhibitors, and novel antimicrotubule agents are among the promising compounds.
  • These agents represent a potential advancement over current treatment options.

Conclusions:

  • Novel therapeutic agents are under investigation for advanced kidney cancer.
  • These new treatments offer hope for patients with refractory disease.
  • Further research and clinical trials are crucial to establish the efficacy of these agents.

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...